Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2020

View Archived Issues

CanSino initiates phase I study of three-component DTcP vaccine candidate

BeiGene opens enrollment in phase I/II study of BGB-10188 for B-cell malignancies and solid tumors

Tonix and University of Alberta collaborate to develop novel COVID-19 vaccines

Winter depression-like behavior is regulated by seasonal changes in the NRF2 pathway

Targeted disruption of aquaporin-1 reduces intraocular pressure: potential gene therapy for glaucoma

Inhibition of P2X7 receptors improves synaptic and behavioral deficits in a Rett syndrome model

Oxidative DNA damage mediates colitis-associated colorectal cancer

New MVP against SVMP

Cynata receives ethics approval for MEND study of Cymerus MSCs in COVID-19

FDA approves IND for phase IIa study of opaganib for COVID-19

FDA clears IND application for phase II study of PLX cells in severe COVID-19

Health Canada grants approval for phase II study of LSALT peptide in patients with COVID-19

SNYE1 mutations associated with cerebellar ataxia and generalized dystonia

First-in-human results presented for SLC-0111 in advanced solid tumors

Cell competition links hyperinsulinemia to cancer

Boehringer Ingelheim identifies new NR2B receptor negative allosteric modulators

New phase I trial evaluates gene therapy to treat severe hemophilia A

New MAP3K5 inhibitors discovered at CJ HealthCare

Shanghai GeneChem synthesizes anti-CLDN128.2 antibodies

Shanghai Yichen Biomed patents EGFR-PD-1 bispecific antibodies

Roche describes new hepatitis B virus cccDNA formation inhibitors

Seattle Genetics initiates phase I study of SGN-TGT in advanced solid tumors and lymphomas

ZFYVE21 is a potential therapeutic target in cardiac allograft vasculopathy

FDA and China NMPA clear IND for Mabspace's humanized Claudin18.2 monoclonal antibody

SCN10A gene loss-of-function variant linked to neuropathy

FDA approves Retevmo for advanced RET-driven lung and thyroid cancers

Oncoinvent recruits for phase I study of Radspherin

FDA approves Lynparza with bevacizumab for HRD-positive advanced ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...